Exploiting open data: A new era in pharmacoinformatics

Future Medicinal Chemistry

Volumn 6, Issue 5, 2014, Pages 503-514

  Goldmann, Daria ^a   Montanari, Floriane ^a   Richter, Lars ^b   Zdrazil, Barbara ^a   Ecker, Gerhard F ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ACTIVITY; BIOMEDICINE; DATA BASE; DRUG INDUSTRY; HUMAN; IC 50; INFORMATION SCIENCE; MACHINE; MEDICAL INFORMATICS; MOLECULAR LIBRARY; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL ASSAY; COMPUTATIONAL BIOLOGY; DATABASES, CHEMICAL; DRUG DISCOVERY; HUMANS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; TRPV CATION CHANNELS;

EID: 84896969286     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.13     Document Type: Review

References (66)

1. Wang Y, Bolton E, Dracheva S et al. An overview of the PubChem BioAssay resource. Nucleic Acids Res. 38(Suppl. 1), D255-D266 (2010).
2. Gaulton A, Bellis LJ, Bento AP et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40(D1), D1100-D1107 (2012).
3. Barnes Mr, Harland L, Foord Sm et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nat. Rev. Drug Discov. 8(9), 701-708 (2009).
4. ChEMBL: European Bioinformatics Institute. www.ebi.ac.uk/chembldb
5. UniProt Consortium. Update on activities at the universal protein resource (UniProt) in 2013. Nucleic Acids Res. 41(D1), D43-D47 (2013).
6. FTP directory. ftp://ftp.ebi.ac.uk/pub/databases/chembl/VM/myChEMBL/ current
7. Seiler KP, George GA, Happ MP et al. ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res. 36(Suppl. 1), D351-D359 (2008).
8. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35(Suppl. 1), D198-D201 (2007).
9. Rosania Gr, Crippen G, Woolf P, States D, Shedden K. A cheminformatic toolkit for mining biomedical knowledge. Pharm. Res. 24(10), 1791-1802 (2007).
10. Sharman JL, Benson HE, Pawson AJ et al. IUPHAR-DB: updated database content and new features. Nucleic Acids Res. 41(D1), D1083-D1088 (2013).
11. IUPHAR-DB. www.iuphardb.org
12. Ozawa N, Shimizu T, Morita R et al. Transporter database, TP-Search: a webaccessible comprehensive database for research in pharmacokinetics of drugs. Pharm. Res. 21(11), 2133-2134 (2004).
13. TP-Search. http://125.206.112.67/tp-search
14. Horn F, Bettler E, Oliveira L, Campagne F, Cohen FE, Vriend G. GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res. 31(1), 294-297 (2003).
15. Seeman P. Drug dissociation constants for neuroreceptors and transporters. In: Receptor Tables. SZ Research, Toronto, Canada (1992).
16. Cutler D, Barbier A, Pestell K. In Brief. Trends Pharm. Sci. 23(6), 258-259 (2002).
17. BindingDB. www.bindingdb.org
18. Berman HM, Westbrook J, Feng Z et al. The protein data bank. Nucleic Acids Res. 28(1), 235-242 (2000).
19. Knox C, Law V, Jewison T et al. DrugBank 3.0: a comprehensive resource for omics research on drugs. Nucleic Acids Res. 39(Suppl. 1), D1035-D1041 (2011).
20. Drugbank. www.drugbank.ca
21. Chembank. http://chembank.broad.harvard.edu
22. Chemspider. www.chemspider.com
23. Azzaoui K, Jacoby E, Senger S et al. Scientific competency questions as the basis for semantically enriched open pharmacological space development. Drug Discov. Today 18(17-18), 843-852 (2013).
24. Open PHACTS. www.openphacts.org
25. Williams AJ, Harland L, Groth P et al. Open PHACTS: semantic interoperability for drug discovery. Drug Discov. Today 17(21-22), 1188-1198 (2012).
26. Degtyarenko K, De Matos P, Ennis M et al. ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36(Suppl. 1), D344-D350 (2008).
27. Ashburner M, Ball CA, Blake JA et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genetics 25(1), 25-29 (2000).
28. Kelder T, Van Iersel MP, Hanspers K et al. WikiPathways: building research communities on biological pathways. Nucleic Acids Res. 40(D1), D1301-D1307 (2012).
29. Bairoch A. The ENZYME database in 2000. Nucleic Acids Res. 28(1), 304-305 (2000).
30. ConceptWiki. http://ops.conceptwiki.org
31. Open PHACTS explorer. www.openphacts.org/explorer
32. McNaught A. The IUPAC international chemical identifier: InChl - a new standard for molecular informatics. Chem. Int. 28(6), 12-16 (2006).
33. Williams AJ, Ekins S, Tkachenko V. Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. Drug Discov. Today 17(13-14), 685-701 (2012).
34. Hu Y, Bajorath J. Growth of ligand-target interaction data in ChEMBL is associated with increasing and activity measurementdependent compound promiscuity. J. Chem. Inf. Model. 52(10), 2550-2558 (2012).
35. Kalliokoski T, Kramer C, Vulpetti A, Gedeck P. Comparability of mixed IC50 data - a statistical analysis. PLoS ONE 8(4), e61007 (2013).
36. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 22(23), 3099-3108 (1973).
37. Tsareva DA, Ecker GF. How far could we go with open data - a case study for TRPV1 antagonists. Mol. Inform. 32(5-6), 555-562 (2013).
38. Bemis Gw, Murcko Ma: The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39(15), 2887-2893 (1996).
39. Zerhouni E. Medicine. The NIH Roadmap. Science 302(5642), 63-72 (2003).
40. Vempati UD, Przydzial MJ, Chung C et al. Formalization, annotation and analysis of diverse drug and probe screening assay datasets using the BioAssay Ontology (BAO). PLoS ONE 7(11), e49198 (2012).
41. BioAssay ontology. http://bioassayontology.org/wp
42. Malone J, Holloway E, Adamusiak T et al. Modeling sample variables with an experimental factor ontology. Bioinformatics 26(8), 1112-1118 (2010).
43. Zdrazil B, Pinto M, Vasanthanathan P et al. Annotating human P-glycoprotein bioassay data. Mol. Inform. 31(8), 599-609 (2012).
44. Visser U, Abeyruwan S, Vempati U, Smith RP, Lemmon V, Schurer SC. BioAssay Ontology (BAO): a semantic description of bioassays and high-throughput screening results. BMC Bioinform. 12, 257 (2011).
45. Rohrer SG, Baumann K. Maximum unbiased validation (MUV) data sets for virtual screening based on PubChem bioactivity data. J. Chem. Inf. Model. 49(2), 169-184 (2009).
46. Feng BY, Shelat A, Doman TN, Guy RK, Shoichet BK. High-throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 1(3), 146-148 (2005).
47. Shoichet BK. Screening in a spirit haunted world. Drug Discov. Today 11(13-14), 607-615 (2006).
48. Bajorath J. Integration of virtual and highthroughput screening. Nat. Rev. Drug Discov. 1(11), 882-894 (2002).
49. Roche O, Schneider P, Zuegge J et al. Development of a virtual screening method for identification of frequent hitters in compound libraries. J. Med. Chem. 45(1), 137-142 (2002).
50. Murray-Rust P, Mitchell JB, Rzepa HS. Communication and re-use of chemical information in bioscience. BMC Bioinform. 6 (2005)
51. Tiikkainen P, Bellis L, Light Y, Franke L. estimating error rates in bioactivity databases. J. Chem. Inf. Model. 53(10), 2499-2505 (2013).
52. Gregori-Puigjane E, Garriga-Sust R, Mestres J. Indexing molecules with chemical graph identifiers. J. Comp. Chem. 32(12), 2638-2646 (2011).
53. Weininger D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J. Chem. Inform. Comp. Sci. 28(1), 31-36 (1988).
54. Ihlenfeldt WD, Gasteiger J. Hash codes for the identification and classification of molecular structure elements. J. Comp. Chem. 15(8), 793-813 (1994).
55. Steger-Hartmann T, Pognan F, Sanz F, Diaz C. In silico prediction of in vivo toxicities (eTOX) - the Innovative Medicines Initiative approach. Toxicol. Lett. 189(Suppl.), S258 (2009).
56. De Bruyn T, Van Westen GJ, Ijzerman AP et al. Structure-based identification of OATP1B1/3 inhibitors. Mol. Pharmacol. 83(6), 1257-1267 (2013).
57. Warner DJ, Chen H, Cantin LD et al. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug Metab. Dispos. 40(12), 2332-2341 (2012).
58. Friedrich CM, Dach H, Gattermayer T, Engelbrecht G, Benkner S, Hofmann-Apitius M. @neuLink: a service-oriented application for biomedical knowledge discovery. Stud. Health Technol. Inform. 138, 165-172 (2008).
59. Schurer SC, Vempati U, Smith R, Southern M, Lemmon V. BioAssay ontology annotations facilitate cross-analysis of diverse high-throughput screening data sets. J. Biomol. Screen. 16(4), 415-426 (2011).
60. Hersey A, Senger S, Overington JP. Open data for drug discovery: learning from the biological community. Future Med. Chem. 4(15), 1865-1867 (2012).
61. Chambers J, Davies M, Gaulton A et al. UniChem: a unified chemical structure crossreferencing and identifier tracking system. J. Cheminform. 5(1), 3 (2013).
62. Smith B, Ashburner M, Rosse C et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat. Biotechnol. 25(11), 1251-1255 (2007).
63. Zdrazil B, Chichester C, Zander Balderud L, Engkvist O, Gaulton A, Overington JP. Transporter assays and assay ontologies: useful tools for drug discovery. Drug Discov. Today Technol. (In Press) (2014).
64. The BioAssay Ontology. http://bioportal.bioontology.org/ontologies/ BAO
65. Orchard S, Al-Lazikani B, Bryant S et al. Minimum information about a bioactive entity (MIABE). Nat. Rev. Drug Discov. 10(9), 661-669 (2011).
66. Persistent uniform resource locators.